(NASDAQ: TELO) Telomir Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 207.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,953.18%.
Telomir Pharmaceuticals's earnings in 2025 is -$11,250,385.On average, 3 Wall Street analysts forecast TELO's earnings for 2025 to be -$13,326,064, with the lowest TELO earnings forecast at -$12,803,474, and the highest TELO earnings forecast at -$13,718,007.
In 2026, TELO is forecast to generate -$9,819,205 in earnings, with the lowest earnings forecast at -$9,434,138 and the highest earnings forecast at -$10,108,005.